Fundraising Fox
Network Bio
4 known investors
Find your way into Network Bio
Sign up to see every warm intro you have to Network Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Network Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Network Bio activates biobanks through securitization and capital infusion, providing research-grade data assets and operational infrastructure for precision medicine and biomedical research.
Investors · 4
Artis Ventureslisted by Artis VenturesSan Francisco · $50K – $25M
How we know: Artis Ventures's portfolio page · a partner's Signal profile · Not right? Tell us
Breyer Capitallisted by Breyer CapitalAustin · $500K – $10M
How we know: Breyer Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Founders FundreportedSan Francisco · $500K – $5M
How we know: a partner's Signal profile · Not right? Tell us
S32reportedPalo Alto
How we know: a partner's Signal profile · Not right? Tell us
Related companies · 8
bioBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
Access BIOAccess Bio develops in vitro diagnostics technology, producing rapid diagnostic tests, molecular tests, analyzers, and COVID-19 tests (including PCR, serology, and antigen testing) to detect malaria and other diseases. It serves international public health agencies and organizations.
BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Engage BioEngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
Character BioCharacter Bio is a patient-driven therapeutics company that combines genomics, longitudinal clinical and imaging data, and machine learning to identify genetic drivers of disease progression and develop new treatments, with a focus on polygenic diseases. It builds deeply-phenotyped patient cohorts by partnering with patients, providers, and scientists to enable clinical genomic research.
Nuvation BioNuvation Bio is a global oncology company that develops novel cancer therapies through its own drug discovery programs and business development, serving cancer patients. Founded in 2018, it became a commercial-stage company in 2025.
Senti BiosciencesSenti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells. The company is a clinical-stage biotech firm leveraging proprietary platform technology across multiple cell types and modalities.
Transition BioTransition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease. The company is a platform-based biotherapeutics developer founded on academic research from the University of Cambridge.
Companies working in the same space as Network Bio.
Frequently asked questions
- What does Network Bio do?
- Network Bio activates biobanks through securitization and capital infusion, providing research-grade data assets and operational infrastructure for precision medicine and biomedical research.
- Who are Network Bio's investors?
- Network Bio's investors include Artis Ventures, Breyer Capital, Founders Fund, S32.